Voulez-vous consulter la version mobile de ce site ?

Biography

Howard Scher

Howard Scher

Howard I. Scher, MD is Co-Chair, Center for Molecular Based Therapy; Head of the Biomarker Development Initiative; Member and Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC); Professor of Medicine at the Weill Cornell Medical College; and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher’s research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC and the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium (PCCTC), and has received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors.

Mani Sendurai A.

Mani Sendurai A.

Sendurai A. Mani is an Associate Professor in the Department of Translational Molecular Pathology at MD Anderson Cancer Center. He is also the co-director of the Metastasis Research Center as well as the Center for Stem Cell and Developmental Biology at MD Anderson Cancer Center. Mani’s laboratory uses various experimental model systems, including cell lines, patient-derived tumor xenografts as well as mouse models to study the role of cancer stem cells (CSCs) in tumor progression. His original finding demonstrating the cancer cells acquire stem cell properties by activating latent embryonic epithelial-mesenchymal transition (EMT) program provided the foundation and explanation for the presence of plasticity within the tumor as well as the development of resistance to various treatments. Dr. Mani earned a Ph.D. from The Indian Institute of Science, Bangalore, India, and he did postdoctoral work with Dr. Robert A. Weinberg at the Whitehead Institute/Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA. He then joined the University of Texas MD Anderson Cancer Center, Houston, Texas as an Assistant Professor and has been promoted to Associate Professor with tenure and continuing his research at MD Anderson. Dr. Mani has received numerous prizes and awards for his research, including a Jimmy V foundation’s V-Scholar Award and The American Cancer Society Research Scholar award.

Jonathan Sleeman

Jonathan Sleeman

Jonathan Sleeman studied Natural Sciences at Trinity College, Cambridge, UK, and received his PhD in 1992 from the University of Cambridge. He subsequently received an EMBO Long Term Fellowship and a Marie Curie Stipendium from the European Union to support postdoctoral work at the Forschungszentrum Karlsruhe (now Karlsruhe Institute of Technology (KIT)), Germany. He was appointed Group Leader at the Institute for Toxicology and Genetics (ITG), FZK in 1997 and deputy director of ITG in 2003. Dr. Sleeman was acting Chair of Genetics at the University of Karlsruhe, Germany from 2004-2007. He took up the position of Professor of Microvascular Biology and Pathobiology at the University of Heidelberg, Germany, in January 2008, and has laboratories at KIT and the Medical Faculty Mannheim. Dr Sleeman’s research aims to understand the cellular and molecular regulation of metastasis and to use this knowledge to develop novel anti-cancer therapies.

Michael Speicher

Michael Speicher

Michael R. Speicher, M.D. is Professor of Human Genetics and Head of the Institute of Human Genetics at the Medical University of Graz in Austria. Dr. Speicher studied computer science at the University of Dortmund (Germany) and graduated with an MD degree from the University of Essen (Germany). He conducted his clinical and scientific training in Human Genetics at the University of Heidelberg (Germany), at Yale University (New Haven, USA), and at the University of Munich (Germany). For many years Dr. Speicher studied chromosome structure and morphology using various molecular cytogenetic approaches and mechanisms of chromosomal instability. His more recent research is focused on hereditary tumor syndromes, the contribution of germline and somatic genomic variants to cancer, and single cell analysis. Current research projects are directed towards methods for the non-invasive monitoring of cancer evolution by analyses of circulating tumor cells and circulating tumor DNA.

Nikolas H. Stoecklein

Nikolas H. Stoecklein

Nikolas Stoecklein is currently a Professor for Experimental Surgical Oncology at the Heinrich-Heine University Düsseldorf (HHU), Germany. His major research interests are minimal residual disease and early systemic disease in cancer. A current focus of his group is to improve CTC-based liquid biopsies. He pioneered Diagnostic Leukapheresis (DLA) for enhanced CTC detection and established workflows to parse CTCs comprehensively at the single cell level to get deeper insights into the biology of systemic progression and therapeutic resistance. Prior joining the HHU, Nikolas obtained post-doctoral training at the Institute of Immunology of the Ludwig-Maximilians-University Munich, Germany, in the group of Christoph Klein. He graduated from the University of Hamburg, Germany, in 1998 where he studied medicine.

Leon Terstappen

Leon Terstappen

Professor Leon WMM Terstappen, MD, PhD is chair of the department of Medical Cell BioPhysics at the University of Twente, The Netherlands. He received his medical degree from the University of Groningen in 1983 and his PhD in 1988 from the University of Twente. In 1987 he started as post-doctoral fellow at the research department of Becton Dickinson Immunocytometry systems in Mountain View CA, USA and held various research positions thereafter. In 1994 he started as Chief Scientific Officer at Immunicon Corporation, Huntingdon Valley, PA, USA and in 2007 he was appointed at the University of Twente. He is an international recognized expert in cytometry and pioneered the detection of rare cells. He was in charge of the development of the CellSearch system, the only FDA cleared platform to enumerate circulating cancer cells in blood, which was awarded the “Prix Galien”, the major prize for in-vitro diagnostics devices. He currently is the program leader of the STW Perspectief program Cancer-ID and co-leader of the EU IMI program CANCER-ID both programs aim to develop and validate “liquid biopsies” technologies for personalized cancer care. Terstappen is a recipient of the Max Fulwyler Award for Innovative Excellence.

Jean Paul Thiery

Jean Paul Thiery

Jean Paul Thiery is Research Director Emeritus at the Comprehensive Cancer Center, Villejuif, France and a Visiting Professor at the School of Medicine of National University of Singapore (NUS). He was until June 2015, Professor and Head of the Biochemistry Department, School of Medicine, NUS. His influential works include pioneering studies in cell adhesion and migration in early embryogenesis and in elucidating the roles of growth factors and adhesion signaling molecules in Epithelial-Mesenchymal Transitions (EMT). Jean Paul Thiery is credited to be the first to propose that EMT controls carcinoma cell invasion and dissemination.

Frédéric Thomas

Frédéric Thomas

Dr. Frédéric Thomas (48 years old, Directeur de Recherches CNRS) has directed 3 research groups over the past 20 years. He has published more than 230 articles in international peer reviewed journals (1995-present), including Nature, Nature Communications, Nature Ecology and Evolution, Evolution, Trends in Ecology and Evolution, Trends in Parasitology, Ecology Letters, Ecology, American Naturalist, Proceedings of the Royal Society, Plos pathogens, Plos Biology, BMC Cancer and Proteomics, and also edited 12 books (two at Oxford University Press, and BIOLOGIE EVOLUTIVE which is now the French reference book). His H- index is 45. Dr Frédéric Thomas has been working on projects relating to evolution and cancer since July 2010, and has since published 52 articles on this topic (+ 14 also actually submitted), including transmissible cancers. He founded with Benjamin Roche in 2012 the CREEC in Montpellier (www.creec.fr), and also edited with him and Beata Ujvari in 2017 Ecology and Evolution of Cancer (Elsevier). In 2016 he initiated with Beata Ujvari (Deakin university Australia) and Rodrigo Hamede (University of Tasmania) a Laboratoire International Associé, mainly to work on transmissible cancers in Tasmanian Devils. Dr Frédéric Thomas obtained in 2012 the CNRS silver medal for excellence in research.

Prof Erik (Rik) Thompson

Prof Erik (Rik) Thompson

Prof Erik (Rik) Thompson is Professor in Breast Cancer Research at the Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT) and Associate Director of IHBI, QUT at the Translational Research Institute (TRI), Brisbane. Rik was involved with early studies associating increased invasiveness of breast cancer cell lines with epithelial mesenchymal transition (EMT), and has ongoing studies on the relationships of epithelial mesenchymal plasticity (EMP) with metastatic potential and therapy resistance in breast cancer. In recent years, through the EMPathy Breast Cancer Network in Australia, he has directed his attention to EMP in circulating tumour cells (CTCs), both in human xenograft models and clinical samples. He co-founded The International EMT Association (TEMTIA) in 2003 in Australia, was President 2013-2015, and convened the 7th international TEMTIA meeting in Melbourne, Australia in 2015.

Robert A. Weinberg

Robert A. Weinberg

An internationally recognized authority on the genetic basis of human cancer, Dr. Robert A. Weinberg is a founding member of the Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research at the Massachusetts Institute of Technology (MIT). He is also the first Director of the Ludwig Cancer Center at MIT. Over the past three decades, Dr. Weinberg has made breakthrough discoveries in the molecular and genetic roots of cancers. His lab discovered the first oncogene in 1982 and the first tumor suppressor gene in 1986. Most recently, Dr. Weinberg and his collogues were the first to define the genetic rules that must be followed in order for a normal human cell to be transformed into a human cancer cell. Dr. Weinberg’s lab is primarily concerned with how oncogenes, their normal counterparts (proto-oncogenes), and tumor suppressor genes fit together in the complex circuitry that controls cell growth. His lab recently succeeded in creating the first genetically defined human cancer cells. Dr. Weinberg is particularly interested in applying this knowledge to improve the diagnosis and treatment of breast cancer. At present his lab seeks to understand how a malicious population of tumor cells, called cancer stem cells, develop their metastatic powers and what biological conditions are required to eliminate them. Author or editor of six books and more than 400 articles, Dr. Weinberg is best known for his comprehensive cancer textbook, “The Biology of Cancer” 2nd edition. His other books, intended for a lay audience, are “One Renegade Cell”, "Racing to the Beginning of the Road: The Search for the Origin of Cancer" and "Genes and the Biology of Cancer," co-authored with Dr. Harold E. Varmus, former Director of the National Institutes of Health. Dr. Weinberg is an elected Member of the U.S. National Academy of Sciences and Fellow of the American Academy of Arts and Sciences. He is also a Member of the American Philosophical Society and the Institute of Medicine. He has received the National Medal of Science (1997), the Wolf Prize in Medicine (2007), the Otto Warburg Medal (2007), and the Breakthrough Prize in Life Sciences (2013)


La Région OCCITANIE
Congress date : May 3-5 2018

Organizing committee

Catherine Alix-Panabières
Klaus Pantel

Download Programme

Programme

Important
Dates

  • 15th December 2017
    End of the early registration fees
  • 1st February 2018
    Abstract submission deadline
  • 22nd March 2018
    Notification of abstract acceptance & Travel awards
  • 15th April 2018
    End of the standard registration fees
  • 3rd May 2018
    Opening of the ISMRC 2018

Photo
gallery

Montpellier Go to the gallery